Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
10/2007
10/09/2007US7279479 Method for the treatment of heart failure
10/09/2007US7279477 Cardiovascular disease, diabetes, acidosis, cancer, obesity; such as 1-butyl-3,3-dimethyl-1-(4-(2,2,2-trifluoro-1-hydroxy-1-trifluoromethyl -ethyl)-phenyl)-thiourea
10/09/2007US7279476 Anticancer agents, antiinflamamtory agents, restenosis, cardiovascular disorders; insertable device
10/09/2007US7279474 example compound: [7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-(1-ethyl-propyl)amine; treatment of irritable bowel disease and inflammatory bowel disease; anxiety; depression
10/09/2007US7279472 cathepsins inhibitors such as N-(4-Cyano-methyl-piperidin-4-yl)-3-cyclohexyl-2-(3-oxo-3H-isoindol-1-ylamino)-propionamide, used for treating autoimmune diseases such as arthritis, multiple sclerosis, asthma and osteoporosis
10/09/2007US7279470 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
10/09/2007US7279468 Integrin ligands
10/09/2007US7279459 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis
10/09/2007US7279330 Method for identifying modulating compounds of neurotransmitters
10/09/2007US7279324 Nucleic acid encoding G-protein coupled receptor with modified DRY motif
10/09/2007US7279318 Reacting the elements such as viruses and other micro-organisms with a synthetic hydrophilic multivalent polymer with a backbone based upon monomer units of N-2-hydroxypropylmethacrylamide, N-(2-Hydroxy ethyl)-L-Glutamine, ethyleneglycol-oligopeptide or dextran monomers and multiple reactive groups
10/09/2007US7279183 Particularly magnesium sulfate, magnesium oxide, magnesium phosphate, or magnesium chloride
10/09/2007US7279156 Apoptotic bodies and/or apoptotic cells are in a liquid suspension along with viable cells.
10/09/2007CA2252084C Cytoprotective compounds
10/09/2007CA2161857C Oxazolidinone derivatives as adhesion receptor antagonists
10/07/2007CA2582394A1 Use of an antiatherothrombotic compound to produce medications for treating vascular disorders
10/04/2007WO2007112135A2 Methods and systems for treating injured cardiac tissue
10/04/2007WO2007112098A2 Uses of diphenyl/diphenylamine carboxylic acids
10/04/2007WO2007111921A1 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
10/04/2007WO2007111528A1 Agent exhibiting a neurotropic, neuromodulator, cerebrovascular and anti- stroke activity
10/04/2007WO2007111350A1 Agent for inhibition of angiogenesis or mesenchymal-type or amoeboid-type invasion of cancer cell
10/04/2007WO2007111306A1 Lipid metabolism ameliorating agent
10/04/2007WO2007111276A1 Novel ester derivative and use thereof
10/04/2007WO2007111214A1 Trehalose compound and pharmaceutical comprising the compound
10/04/2007WO2007111212A1 Triazolone derivative
10/04/2007WO2007111203A1 Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer
10/04/2007WO2007110755A1 Prophylaxis or treatment of cardiovascular inflammation
10/04/2007WO2007110730A2 Varenicline standards and impurity controls
10/04/2007WO2007110364A1 Benzothiazoles having histamine h3 receptor activity
10/04/2007WO2007081530A3 Endoluminal medical device for local delivery of cathepsin inhibitors
10/04/2007WO2007074399A3 Process for the preparation of tetrazolyl compounds
10/04/2007WO2007060215A3 (r)-arylkylamino derivatives and pharmaceutical compositions containing them
10/04/2007WO2007047205A3 Enzyme inhibitors of pai-1
10/04/2007WO2006094810A3 Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
10/04/2007WO2006030306A8 Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
10/04/2007WO2005032462A3 Glucocerebroside treatment of disease
10/04/2007US20070232692 Method of Treating Cancer Using Dithiocarbamate Derivatives
10/04/2007US20070232683 Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
10/04/2007US20070232613 4-(1-Piperazinyl)-2(1H)-quinolone and 4-(1-piperazinyl)quinoline derivatives, e.g., 3-nitro- or 3-alkoxycarbonyl-1-methyl-4-[4-thiophene-2-carbonyl)-piperazine-1-yl]-1H-quinolin-2-one; antitumor and angiogenesis inhibitor, antiinflammatory, antidiabetic agent, autoimmune disorder
10/04/2007US20070232597 Compounds, Compositions, and Methods
10/04/2007US20070232586 Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof
10/04/2007US20070232580 Novel sterol/stanol nitroderivatives and use thereof in treating or preventing cardiovascular disease, its underlying conditions and other disorders
10/04/2007US20070232579 Nitrated Lipids and Methods of Making and Using Thereof
10/04/2007US20070232571 Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase
10/04/2007US20070232551 Treatment for Cardiovascular Disease
10/04/2007US20070231863 Expression vector comprising nucleotide sequences coding homeobox gene for use in identifying modulators for treatment and prevention of nervous system and seizure disorders
10/04/2007US20070231859 Novel scavenger receptor
10/04/2007US20070231849 Hyperpolarizing with potential-sensitive fluorescent dye and isoosmolar sodium-ion-free buffer, incubating, determining membrane potential, adding sodium, recording change in potential; voltage sensitive oxonol dyes; sodium channel modulators; high throughput screening; fluorescent imaging plate reader
10/04/2007US20070231830 Using competitive binding assays to identify peptide modulators for signal transduction
10/04/2007US20070231404 Preparation derived from shark cartilage for treatment of diseases related to excessive PHF or excessive intracellular calcium
10/04/2007US20070231394 Agent for Removing Circulatory Dysfunction Factor
10/04/2007US20070231376 Methods and compositions for modulating axonal outgrowth of central nervous system neurons
10/04/2007US20070231310 Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells
10/04/2007US20070231309 Cell populations which co-express CD49c and CD90
10/04/2007US20070231267 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands
10/04/2007US20070231266 Diagnosis of macrophage mediated disease
10/04/2007DE102006016285A1 Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials
10/04/2007DE102006014688A1 Azolopyridin-3-on-derivate als Inhibitoren von Lipasen und Phospholipasen Azolopyridin-3-one derivatives as inhibitors of lipases, and phospholipases
10/04/2007DE102006014685A1 Imidazo-pyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholiphasen Imidazo-pyridin-2-one derivatives as inhibitors of lipases, and Phospholiphasen
10/04/2007DE102006014420A1 New 5-D-fructose dehydrogenase in combination with an enzyme, e.g. glucose isomerase, useful for preventing or treating adiposity
10/04/2007DE102006014390A1 Assoziate von Xanthogenaten mit Cyclodextrinen und ihre Verwendung Associates of xanthates with cyclodextrins and their use
10/04/2007DE102006012874A1 Mittel zur effektiven Senkung der Konzentrationen des C-reaktiven Proteins (CRP) Means for effectively reducing the concentrations of C-reactive protein (CRP)
10/04/2007DE10129119B4 Kristalline Salze von Benzoylbenzofuran-Derivaten, insbesondere Crystalline salts of benzoylbenzofuran-derivatives, in particular von[2-(4-{1-[2-((S)-sec.-Butoxycarbonylmethyl)-benzofuran-3-carbonyl]-methanoyl}-2,6-diiod-phenoxy)-ethyl]-diethylamino und [2-(4-{1-[(3-Methyl-2-(S)-Butoxycarbonylmethyl)-benzofuran-3-carbonyl]- methanoyl}-2,6-diiodphenoxy)-ethyl]-diethylamino, deren Verwendung und Herstellung sowie diese Salze enthaltende Arzneimittel and [2- (4- {1 - [(3-methyl-2- (S) -Butoxycarbonylmethyl) benzofuran-3-carbonyl] - methanoyl} -2,6-diiodphenoxy) -ethyl] -diethylamino, their use and preparation and pharmaceutical compositions containing these salts
10/04/2007CA2681639A1 Compounds and methods for treatment of disorders associated with er stress
10/04/2007CA2647512A1 Substance exhibiting neuromodulator activity
10/04/2007CA2647423A1 Triazolone derivative
10/04/2007CA2645581A1 Benzothiazoles having histamine h3 receptor activity
10/04/2007CA2645488A1 Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
10/04/2007CA2645487A1 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
10/04/2007CA2644448A1 Varenicline standards and impurity controls
10/04/2007CA2644369A1 Amide derivatives and their application for the treatment of g protein related diseases
10/03/2007EP1840125A2 Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics
10/03/2007EP1839675A1 Novel method of protecting ischemic cardiopathy
10/03/2007EP1839670A2 Modified Annexin Proteins and Methods for preventing Thrombosis
10/03/2007EP1839669A1 Novel angiogensis inhibitor
10/03/2007EP1839667A2 Cell-based gene therapy for the pulmonary system
10/03/2007EP1839666A1 Composition for treating hypertension comprising tribomechanically activated zeolites
10/03/2007EP1839663A1 Blood cholesterol reducing oral composition
10/03/2007EP1839661A2 Pipecolic acid-containing antidiabetic compositions
10/03/2007EP1839659A2 Chemicals compounds
10/03/2007EP1839648A2 An inhalation system
10/03/2007EP1838840A2 Use of cultured three-dimensional tissue for treating congestive heart failure
10/03/2007EP1838710A1 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
10/03/2007EP1838694A1 5-thioxo-1,5-dihydro-2h-pyrrol-2-one derivatives as liver x receptor modulators
10/03/2007EP1838690A2 Compounds with kv4 ion channel activity
10/03/2007EP1838687A1 Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
10/03/2007EP1838686A1 Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
10/03/2007EP1838685A1 Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
10/03/2007EP1838684A1 Non-anilinic derivatives of isothiazol-3(2h)-thione 1,1-dioxides as liver x receptor modulators
10/03/2007EP1838670A1 Process for the preparation of carvedilol and its enantiomers
10/03/2007EP1838662A1 Squaric acid derivatives
10/03/2007EP1838392A2 Selenium-containing medicaments for the prevention or treatment of endothelial vascular diseases
10/03/2007EP1838334A1 Use of a trpc channel for the treatment of a cardiovascular disease
10/03/2007EP1838323A2 Cardiovascular compositions
10/03/2007EP1838315A1 Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
10/03/2007EP1838304A2 Heterocyclic aspartyl protease inhibitors
10/03/2007EP1838296A2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases
10/03/2007EP1648906B1 Organosilicon compounds and their use
10/03/2007EP1613298A4 Lysophosphatidic acid analogs and inhibition of neointima formation
10/03/2007EP1490361B1 Polycyclic compounds as potent alpha2-adrenoceptor antagonists
1 ... 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 ... 1595